Incidence of Tumour Lysis Syndrome in Patients with Acute Myeloid Leukemia During Initiation of Therapy with Azacitidine and Venetoclax: A Retrospective Chart Review from a Canadian Single-Centre Perspective
Current Oncology · 02.04.2025 · 32 (4) · 213
DOI: 10.3390/curroncol32040213 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, online erschienen am 02.04.2025. Verfasst von Tana Saiyin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, The Ottawa Hospital, University of Ottawa, 501 Smyth Road, Ottawa, ON K1H 8L6, Canada. Hauptthemen laut MEDLINE: Tumor Lysis Syndrome, Sulfonamides, Leukemia, Myeloid, Acute, Azacitidine. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Azacitidine and venetoclax (Aza-Ven) are part of a new standard of care for elderly patients with Acute Myeloid Leukemia (AML) [In line with recommendations, patients with AML at our centre were routinely admitted during initiation of Aza-Ven for close monitoring for tumour lysis syndrome (TLS). However, hospitalization impacts patient experience and is a significant resource burden. The objectives of this study were to evaluate the incidence of TLS in this population and identify patients who could safely initiate therapy in our outpatient facility. Of the 48 patients who commenced Aza-Ven as inpatients, the incidence of TLS was 25% using Cairo–Bishop (CB) diagnostic criteria but was mostly due to transient increases in uric acid, phosphate or potassium that remained within the normal laboratory reference range. Using Howard diagnostic criteria, TLS incidence was only 2%. Patients who developed CB TLS had a significantly higher baseline white blood count (WBC; p = 0.01). Patients with WBC of less than 30 × 109/L subsequently completed outpatient initiation of Aza-Ven (n = 15). Only one of these patients developed mild, transient TLS by CB criteria but not by Howard criteria. Our results demonstrate that a significant portion of patients could safely initiate Aza-Ven in our outpatient facility and avoid unnecessary hospitalization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, The Ottawa Hospital, University of Ottawa, 501 Smyth Road, Ottawa, ON K1H 8L6, Canada.
- The Ottawa Hospital Leukemia Program, Department of Medicine, Division of Hematology, Ottawa Hospital Research Institute, University of Ottawa, 501 Smyth Road, Ottawa, ON K1H 8L6, Canada.
- Department of Pharmacy, The Ottawa Hospital, 501 Smyth Road, Ottawa, ON K1H 8L6, Canada.
ORCID-Profile: Mitchell Sabloff, Tina Crosbie, Jill Fulcher
Zitieren
APA
Saiyin, T., Christou, G., Sabloff, M., Crosbie, T., Nguyen-Tham, K. M., & Fulcher, J. (2025). Incidence of Tumour Lysis Syndrome in Patients with Acute Myeloid Leukemia During Initiation of Therapy with Azacitidine and Venetoclax: A Retrospective Chart Review from a Canadian Single-Centre Perspective. Current Oncology, 32(4), 213. https://doi.org/10.3390/curroncol32040213
Vancouver
Saiyin T, Christou G, Sabloff M, Crosbie T, Nguyen-Tham KM, Fulcher J. Incidence of Tumour Lysis Syndrome in Patients with Acute Myeloid Leukemia During Initiation of Therapy with Azacitidine and Venetoclax: A Retrospective Chart Review from a Canadian Single-Centre Perspective. Current Oncology. 2025;32(4):213. doi:10.3390/curroncol32040213
BibTeX
@article{Saiyin2025,
author = {Saiyin, Tana and Christou, Grace and Sabloff, Mitchell and Crosbie, Tina and Nguyen-Tham, Kim-My and Fulcher, Jill},
title = {Incidence of Tumour Lysis Syndrome in Patients with Acute Myeloid Leukemia During Initiation of Therapy with Azacitidine and Venetoclax: A Retrospective Chart Review from a Canadian Single-Centre Perspective},
journal = {Current Oncology},
year = {2025},
volume = {32},
number = {4},
pages = {213},
doi = {10.3390/curroncol32040213}
}
EUVIMED